Former head of psychiatry products at FDA joins psychedelic drug developer…
…the company is also developing novel molecules based on other psychedelic compounds. The company has filed 12 provisional patent applications for novel psychedelic molecules… Thomas Laughren, a medical doctor who served as the director of the U.S. Food and Drug Administration’s division of psychiatry products for nearly three decades… …left his post at the FDA…
Recent Comments